deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03410030

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM)

Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer

Sponsor: Barts Cancer Institute

Conditions Pancreas Cancer Pancreas Metastases Pancreatic Adenocarcinoma Resectable Pancreatic Cancer Pancreatic Ductal Adenocarcinoma
Interventions Ascorbic Acid Cisplatin Gemcitabine Paclitaxel protein-bound
Updated 16 times since 2018 Last updated: Apr 13, 2023 Started: Dec 15, 2017 Primary completion: Sep 14, 2021 Completion: Jan 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03410030, this PHASE1/PHASE2 trial focuses on Pancreas Cancer and Pancreas Metastases and remains completed. Sponsored by Barts Cancer Institute, it has been updated 16 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~May 2023 · 14 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Mar 2022 — May 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2022 — Mar 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Barts Cancer Institute
  • Cancer Research UK
  • Cold Spring Harbor Laboratory
  • HonorHealth Research Institute
  • Imaging Endpoints
  • Lustgarten Foundation
  • Princeton University
  • Salk Institute for Biological Studies
  • Stand Up To Cancer
  • Translational Genomics Research Institute
  • University of Arizona
Data source: HonorHealth Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations